Biosimilars Council Launches Educational Research for Leading Biosimilar Research

Washington, D.C. (December 14, 2022) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today announced the launch of its “Research and Studies,” online resource. The new resource captures the growing body of scientific evidence on the safety, efficacy, and cost savings of biosimilar medicines.

“Biosimilar medicines are safe, effective, and more affordable treatment options for patients,” said Craig Burton, Executive Director of the Biosimilars Council. “But peer-reviewed studies can be time-consuming to sift through. We are proud to launch the Research and Studies resource to give patients, caregivers, health care providers, and policymakers an easy way to access important information about biosimilars.”

The Research and Studies page is easily navigable, allowing visitors to search for biosimilar studies across a range of relevant categories to easily find the information they need.

Click here to visit the Research and Studies page.

MEDIA CONTACT:

Susan Reilly

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.